The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Life Science Nation’s 2027 RESI conference calendar will connect early-stage life science companies with global investors, pharma partners, and industry leaders across four major life science hubs: San Francisco, Tokyo, Philadelphia, and Boston.

The year begins during JPM week and continues through Asia, BIO International Convention week in Philadelphia, and Boston’s biotech week in September. Each event is designed to help emerging companies build the investor relationships and strategic partnerships needed to move their companies forward.

RESI JPM 2027: January 11–12

San Francisco Marriott Marquis, San Francisco

Registration is now open for RESI JPM 2027.

Held concurrently with JPM Healthcare Week, RESI JPM brings early-stage companies into San Francisco during one of the world’s largest annual gatherings for healthcare investment and business development. The two-day in-person conference will be followed by virtual partnering on January 13, 18, and 19.

Previous RESI JPM conferences have drawn more than 1,000 attendees, including over 600 early-stage life science investors, innovators, and industry experts. For companies raising capital, pursuing strategic partnerships, or preparing for a major financing milestone, RESI offers a focused setting to make the most of the week.

RESI Asia Japan 2027: April 13

ANA InterContinental, Tokyo

RESI Asia Japan launches in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster.

Japan represents one of the life science industry’s most valuable and least accessible markets. Its leading pharmaceutical companies are active licensors and acquirers of external innovation, while the country offers deep clinical development capabilities and a progressive regulatory pathway for regenerative medicine, cell therapy, and gene therapy.

RESI Asia Japan will create a direct bridge between Japan’s world-class science ecosystem and global capital and partnering networks. The event is part of a broader collaboration between Life Science Nation and KBIC focused on strengthening commercialization pathways, entrepreneur education, capital formation, and international business development for Japanese life science companies.

RESI Philadelphia 2027: June 7

Convene, Philadelphia

RESI Philadelphia will take place during BIO International Convention week, complementing the broader industry activity in the city with a dedicated forum for early-stage companies and active investors.

Philadelphia is a leading center for cell and gene therapy, biopharma, medical innovation, and academic research. RESI provides companies and investors attending BIO week with a targeted environment for investor partnering, live pitch opportunities, and conversations that can turn promising science into fundable, strategic opportunities.

Virtual partnering dates will be announced soon.

RESI Boston 2027: September 22

Westin Copley Place, Boston

RESI returns to Boston during biotech week, bringing the global early-stage life science investment community together in one of the world’s most important innovation hubs.

Boston’s unmatched concentration of founders, investors, academic institutions, biotech companies, and strategic partners makes it an essential stop on the RESI calendar. The in-person event will offer targeted partnering, investor panels, educational programming, and the Innovator’s Pitch Challenge for companies seeking to raise visibility and advance fundraising conversations.

Virtual partnering dates will be announced soon.

A Global RESI Run

The 2027 lineup offers companies multiple opportunities throughout the year to engage the Life Science Nation network, deepen relationships with investors and strategic partners, and access new regional markets.

RESI JPM: January 11–12, San Francisco
RESI Asia Japan: April 13, Tokyo
RESI Philadelphia: June 7, Philadelphia
RESI Boston: September 22, Boston

Registration is now open for RESI JPM 2027. Register by October 2 to save $900 with Super Early Bird pricing. Learn more at resiconference.com.

RESI Boston 2026 Innovator’s Pitch Challenge Finalists

September 1, 2026September 1, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

The Innovator’s Pitch Challenge (IPC) showcases early-stage companies developing breakthrough technologies across key sectors of life science and returns to RESI Boston with more than 65 innovative companies selected to pitch across 20 sessions over two days, September 22–23, 2026.

Each finalist will present to panels of active life science investors and industry leaders in sector-focused sessions spanning biotech, medtech, diagnostics, digital health, and more. The program gives fundraising companies the opportunity to share their technologies, receive practical feedback, and connect directly with investors and strategic partners seeking new opportunities.

For attendees, IPC is a chance to discover emerging companies and hear directly from the founders behind them. Finalists will also be available throughout the event exhibiting, networking, and attendees participating in partnering can schedule one-on-one meetings to continue the conversation.

Join Life Science Nation at RESI Boston during Biotech Week for two full days of company pitches, investor insights, and targeted partnering.

Meet the RESI Boston Innovator’s Pitch Challenge Finalists:

Bayer Co.Lab Joins RESI Boston 2026 as Title Sponsor

September 1, 2026September 3, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to welcome Bayer Co.Lab as a Title Sponsor of RESI Boston 2026, taking place September 22-23 at the Westin Copley Place in Boston, with virtual partnering continuing September 25 and 28-29.

Bayer Co.Lab is Bayer’s global network of life science incubators supporting early-stage entrepreneurs developing breakthrough technologies. By connecting emerging companies with scientific expertise, mentorship, infrastructure, and Bayer’s broader global network, Co.Lab provides an environment designed to help innovators advance promising science and build the relationships needed for future growth.

Bayer Co.Lab’s mission is closely aligned with RESI’s focus on connecting early-stage life science and healthcare companies with investors, strategic partners, and industry leaders who can accelerate breakthrough therapies.

Bayer Co.Lab’s will be sponsoring a 2-hour session at RESI Boston 2026:

Connecting Asian Biotech Innovation with Global Partners: A Bayer Co.Lab Showcase

Tuesday, September 22, 2:00 – 4:00pm EST

The showcase will bring seven emerging biotechnology companies from Korea and Japan to the RESI stage, highlighting innovative approaches across various therapeutic modalities.

RSVP for Bayer Co.Lab Showcase

artiCure | Korea

Tumor-selective replicating gene therapy targeting solid tumors

Crafton Biotechnology | Japan

mRNA therapeutics supported by advanced computational approaches

Curigin | Korea

RNA-based therapeutic technologies across multiple disease areas

Elisigen | Korea

Next-generation gene therapy with programs in ophthalmology

Genome & Company | Korea

Microbiome-driven therapeutic discovery and development

ILIAS Biologics | Korea

Exosome-based therapeutics for inflammatory and fibrotic diseases

Kanjin Therapeutics | Japan

RNA therapeutics, including siRNA and antisense approaches, for areas of unmet medical need

The program reflects a growing opportunity to connect promising innovation emerging from Asian biotech ecosystems with global pharmaceutical partners, investors, and other strategic collaborators. By bringing Korean and Japanese companies directly into the RESI community, the showcase will create a forum for companies to present their science, build international relationships, and explore pathways for global development and partnership.

Meet Bayer at RESI Boston

Bayer will have a strong presence at RESI Boston, with senior representatives spanning Co.Lab and BD & Licensing departments.

Alberto Nobili Sr. Director, Strategy and Portfolio at Co.Lab	Nobuhiro Kazama Head of Collaborate to Cure Japan Hub	Ilona Gutcher Senior Director, BD&L Oncology
Carla Klattenhoff Senior Director / Scientific US Lead for Research and Early Development in CV, Renal and Immunology	Shivaranjani Sridharan Executive Director, Business Development & Licensing

Their participation gives RESI attendees an opportunity to engage with Bayer leaders representing multiple areas of scientific and strategic interest and to gain greater insight into how a global pharmaceutical company approaches external innovation and collaboration.

Bringing Global Innovators Together in Boston

RESI has always been built around a simple idea: great science can come from anywhere, but moving it forward requires the right connections.

Bayer Co.Lab’s participation as Title Sponsor of RESI Boston 2026 reinforces that mission. From supporting emerging entrepreneurs to creating new connections between Asian biotech innovators and the global life science ecosystem, the collaboration will bring another important dimension to this year’s RESI Boston.

Join Bayer Co.Lab and the global early-stage life science community at RESI Boston 2026!

Building the Innovation Bridge Between Japan and the World

August 25, 2026August 25, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Japan has world-class science, deep pharmaceutical expertise, and a rich pipeline of emerging life science technology. It is now delivering an innovation bridge that connects that innovation to the global life science community.

At RESI Boston 2026, our 8th annual Global Family Office BioForum Luncheon will bring together international family offices for a private, invitation-only conversation about the emerging bridge between Japan and the rest of the world. I will be joined by Keiko Kobayashi of the Kobe Biomedical Innovation Cluster (KBIC) and Rick Berenson, Managing Director of Venzyme Catalyst.

KBIC is one of Japan’s largest life science clusters, and our work together is centered on three objectives: helping Japanese technology assets enter the global arena, bringing international investors and strategic partners closer to Japan’s innovation ecosystem, and fostering cross-border investment syndicates that connect Japanese and international investors around opportunities in both markets.

The pieces are coming together. KBIC brings the Japanese ecosystem, company pipeline, and government relationships. Venzyme Catalyst brings early-stage assessment, shaping, and de-risking. LSN brings commercialization preparation, RESI, BD Assist, and its global network of investors and licensing partners. Keiko will share what KBIC is building in Japan, while Rick and I will explain how the commercialization engine connects regional innovation to the global marketplace.

Then we will do what has made the BioForum work for eight years: get out of the way and let the room work. The real value is the conversation among family offices as they compare perspectives, share experiences, and build relationships with peers. Attendance is limited and by invitation only. Family offices interested in attending can reply to this newsletter or contact Life Science Nation to request an invitation.

Global Family Office BioForum Luncheon
Tuesday, September 22, 2026, 12:00 to 1:00 pm
Westin Copley Place, Boston
Private and invitation only

RSVP for GFOB Here

Featuring:

Dennis Ford

Founder of Life Science Nation, Creator of RESI, and Architect of LSN Labs

Rick Berenson

Managing Director, Venzyme Catalyst

Keiko Kobayashi

Business Strategies, Head of International Ecosystem Development, KBIC

Building the Future of Chronic Disease Care

August 25, 2026August 25, 2026 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Chronic diseases represent one of healthcare’s greatest challenges and one of its largest opportunities for innovation. As the global burden of chronic conditions continues to grow, investors are looking for solutions that can improve outcomes, reduce long-term costs, and fundamentally change how patients manage their health.

At RESI Boston, the panel Building the Future of Chronic Disease Care: Innovation Across Therapeutics, Devices, and Digital Health will bring together investors to discuss where they see the most compelling opportunities across the chronic disease landscape.

The conversation will explore innovation across therapeutics, medical devices, diagnostics, and digital health, as well as the evolving reimbursement and adoption models that can determine whether a promising technology successfully reaches patients. Panelists will also share what they look for when evaluating early-stage companies, from clinical and commercial validation to differentiation, scalability, and a clear path to market.

Chronic Disease Panelists
Soyoung Park 1004 Venture Partners (Moderator)	Gopal Chopra Validare Capital	Navin Govind Evidence Ventures
Nune Martiros Paladin Capital Group	John Tremblay Launchpad Venture Group

For early-stage founders developing solutions for chronic disease, this session offers an opportunity to hear directly from investors about what is attracting capital today and what companies need to demonstrate to stand out in a large and increasingly competitive market.

Join the conversation at RESI Boston, September 22–23 at the Westin Copley Place, and connect with investors, strategic partners, and fellow innovators advancing the next generation of healthcare.

More Investors. More Opportunities. More Momentum.

August 11, 2026August 11, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Investor interest in RESI Boston is building quickly as the launch of the RESI partnering platform approaches on Monday, August 17. With partnering just days away, investor registrations are expected to accelerate further as firms prepare to identify companies and begin scheduling one-on-one meetings.

In five days of investor registration, more than 30 investor firms signed up to participate, reinforcing RESI’s position as one of the premier partnering events for early-stage life science companies seeking capital and strategic partnerships.

Recently Confirmed Investors (Last 5 Days)

Explore the full RESI Boston investor list here.

These new registrations join a growing community of investors from across venture capital, corporate venture, family offices, angel groups, foundations, and strategic investment organizations, creating even more opportunities for meaningful one-on-one meetings.

🏷️ Save $300 on RESI Boston Registration

Secure your pass before Early Bird rates end this Friday, August 14th to get full access to investor partnering!

Already, more than 200 investors representing over 150 global investor firms have registered for RESI Boston, with additional investors continuing to join each week.

As the investor roster continues to grow, so do the opportunities to connect with the partners who can help move your company forward.

Register now to join one of the industry’s most active life science partnering events. Early Bird pricing ends Friday, August 14, giving attendees one last opportunity to save $300 before standard rates take effect.

Partnering Launches August 17 for RESI Boston September 2026

August 11, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

RESI Boston September 2026 brings together one of the largest gatherings of early-stage life science investors, pharmaceutical and medtech business development professionals, strategic partners, and innovators during Biotech Week Boston. With two days of in-person networking, educational panels, company presentations, the Innovator’s Pitch Challenge, an active exhibit hall, and dedicated one-on-one partnering, RESI is designed to help emerging life science companies build the relationships that drive fundraising, licensing, strategic partnerships, and commercialization.

One of the event’s most valuable features launches Monday, August 17: the RESI partnering platform.

Beginning August 17, registered attendees can start scheduling one-on-one meetings with investors, pharmaceutical business development teams, strategic partners, and service providers well in advance of the conference.

The RESI series continues to be one of the world’s largest early-stage life science partnering events, bringing together hundreds of active investors and strategic partners focused on biotechnology, AI, medical devices, diagnostics, digital health, and life science tools. Whether attending in person or virtually, participants can use Life Science Nation’s (LSN) proprietary partnering platform to identify organizations that align with their technology, stage of development, therapeutic focus, and fundraising objectives.

Launching your partnering outreach early is one of the best ways to maximize your RESI experience. Companies that complete their profiles and begin requesting meetings as soon as partnering opens gain greater visibility and have more opportunities to secure valuable conversations before schedules begin to fill.

To help attendees make the most of the partnering platform, Life Science Nation will host a complimentary RESI Boston Partnering Tutorial webinar on Tuesday, August 18, at 9:00 AM MT. During this interactive session, LSN staff will demonstrate how to:

Build a compelling partnering profile
Identify investors and strategic partners that best fit your company
Develop an outreach strategy that increases meeting acceptance
Manage meeting requests and follow up effectively
Leverage the partnering platform and conference resources to maximize your RESI experience

🎓 Free Webinar: RESI Partnering Tutorial

Learn outreach strategies to maximize your 1-on-1 investor meetings. Tuesday, Aug 18 @ 11:00 AM ET

Whether you are attending RESI for the first time or are a returning participant, this tutorial offers practical strategies to help you secure more meaningful meetings and maximize your return on investment.

Register now to secure your $300 Early Bird savings before August 14, complete your partnering profile, begin requesting meetings when the platform opens on August 17, and join the complimentary Partnering Tutorial on August 18 to position your company for a productive and successful RESI Boston September 2026.

🏷️ Save $300 on RESI Boston Registration

Secure your pass before Early Bird rates end this Friday, August 14th to get full access to investor partnering!